Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386256545> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4386256545 endingPage "OF9" @default.
- W4386256545 startingPage "OF1" @default.
- W4386256545 abstract "This open-label, single-arm, phase 2 study evaluated the vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) rivoceranib in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).Eligible patients had confirmed disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) with ≥20% increase in radiologically or clinically measurable lesions or appearance of new lesions within the preceding 6 months. Patients received oral rivoceranib 700 mg once daily. Primary outcomes were objective response rate (ORR) by investigator review and by blinded independent review committee (BIRC).Eighty patients were enrolled and 72 were efficacy evaluable. Seventy-four patients had distant metastases and 49 received prior systemic treatment (14 received VEGFR TKIs). Per investigator and BIRC, respectively, ORR was 15.3% (95% CI, 7.9-25.7) and 9.7% (95% CI, 4.0-19.0); median duration of response was 14.9 months (95% CI, 4.9-17.3) and 7.2 months (95% CI, 3.5-8.4); and median progression-free survival was 9.0 months (95% CI, 7.3-11.5) and 9.0 months (95% CI, 7.7-11.5). Grade ≥3 treatment-related adverse events occurred in 56 patients (70.0%); the most common were hypertension (34, 42.5%) and stomatitis (6, 7.5%). Four grade 5 events occurred with one attributed to rivoceranib (epistaxis). Sixty-eight patients (85.0%) had ≥1 dose modifications and 16 patients (20.0%) discontinued rivoceranib for toxicity.In patients with progressing R/M ACC, rivoceranib demonstrated anti-tumor activity and a manageable safety profile consistent with other VEGFR TKIs." @default.
- W4386256545 created "2023-08-30" @default.
- W4386256545 creator A5013890164 @default.
- W4386256545 creator A5022036818 @default.
- W4386256545 creator A5026459010 @default.
- W4386256545 creator A5034739279 @default.
- W4386256545 creator A5036572642 @default.
- W4386256545 creator A5036875036 @default.
- W4386256545 creator A5038563211 @default.
- W4386256545 creator A5043535723 @default.
- W4386256545 creator A5058393482 @default.
- W4386256545 creator A5071669347 @default.
- W4386256545 creator A5080295544 @default.
- W4386256545 creator A5081712437 @default.
- W4386256545 creator A5088419169 @default.
- W4386256545 creator A5090804469 @default.
- W4386256545 date "2023-10-03" @default.
- W4386256545 modified "2023-10-05" @default.
- W4386256545 title "A Phase 2 Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma" @default.
- W4386256545 doi "https://doi.org/10.1158/1078-0432.ccr-23-1030" @default.
- W4386256545 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37643133" @default.
- W4386256545 hasPublicationYear "2023" @default.
- W4386256545 type Work @default.
- W4386256545 citedByCount "0" @default.
- W4386256545 crossrefType "journal-article" @default.
- W4386256545 hasAuthorship W4386256545A5013890164 @default.
- W4386256545 hasAuthorship W4386256545A5022036818 @default.
- W4386256545 hasAuthorship W4386256545A5026459010 @default.
- W4386256545 hasAuthorship W4386256545A5034739279 @default.
- W4386256545 hasAuthorship W4386256545A5036572642 @default.
- W4386256545 hasAuthorship W4386256545A5036875036 @default.
- W4386256545 hasAuthorship W4386256545A5038563211 @default.
- W4386256545 hasAuthorship W4386256545A5043535723 @default.
- W4386256545 hasAuthorship W4386256545A5058393482 @default.
- W4386256545 hasAuthorship W4386256545A5071669347 @default.
- W4386256545 hasAuthorship W4386256545A5080295544 @default.
- W4386256545 hasAuthorship W4386256545A5081712437 @default.
- W4386256545 hasAuthorship W4386256545A5088419169 @default.
- W4386256545 hasAuthorship W4386256545A5090804469 @default.
- W4386256545 hasBestOaLocation W43862565451 @default.
- W4386256545 hasConcept C126322002 @default.
- W4386256545 hasConcept C141071460 @default.
- W4386256545 hasConcept C167734588 @default.
- W4386256545 hasConcept C197934379 @default.
- W4386256545 hasConcept C2777025900 @default.
- W4386256545 hasConcept C2777546739 @default.
- W4386256545 hasConcept C2779051857 @default.
- W4386256545 hasConcept C2779231225 @default.
- W4386256545 hasConcept C2779984678 @default.
- W4386256545 hasConcept C29730261 @default.
- W4386256545 hasConcept C31760486 @default.
- W4386256545 hasConcept C71924100 @default.
- W4386256545 hasConcept C90924648 @default.
- W4386256545 hasConceptScore W4386256545C126322002 @default.
- W4386256545 hasConceptScore W4386256545C141071460 @default.
- W4386256545 hasConceptScore W4386256545C167734588 @default.
- W4386256545 hasConceptScore W4386256545C197934379 @default.
- W4386256545 hasConceptScore W4386256545C2777025900 @default.
- W4386256545 hasConceptScore W4386256545C2777546739 @default.
- W4386256545 hasConceptScore W4386256545C2779051857 @default.
- W4386256545 hasConceptScore W4386256545C2779231225 @default.
- W4386256545 hasConceptScore W4386256545C2779984678 @default.
- W4386256545 hasConceptScore W4386256545C29730261 @default.
- W4386256545 hasConceptScore W4386256545C31760486 @default.
- W4386256545 hasConceptScore W4386256545C71924100 @default.
- W4386256545 hasConceptScore W4386256545C90924648 @default.
- W4386256545 hasLocation W43862565451 @default.
- W4386256545 hasLocation W43862565452 @default.
- W4386256545 hasOpenAccess W4386256545 @default.
- W4386256545 hasPrimaryLocation W43862565451 @default.
- W4386256545 hasRelatedWork W2003938723 @default.
- W4386256545 hasRelatedWork W2047967234 @default.
- W4386256545 hasRelatedWork W2118496982 @default.
- W4386256545 hasRelatedWork W2356374822 @default.
- W4386256545 hasRelatedWork W2417881752 @default.
- W4386256545 hasRelatedWork W2439875401 @default.
- W4386256545 hasRelatedWork W3102005587 @default.
- W4386256545 hasRelatedWork W4238867864 @default.
- W4386256545 hasRelatedWork W4384922324 @default.
- W4386256545 hasRelatedWork W2525756941 @default.
- W4386256545 isParatext "false" @default.
- W4386256545 isRetracted "false" @default.
- W4386256545 workType "article" @default.